Shares of Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $24.00.
BBNX has been the subject of several recent analyst reports. Barclays initiated coverage on shares of Beta Bionics in a report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price objective for the company. Robert W. Baird lifted their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. The Goldman Sachs Group boosted their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wells Fargo & Company started coverage on shares of Beta Bionics in a research report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 target price for the company. Finally, William Blair initiated coverage on shares of Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating for the company.
Check Out Our Latest Stock Report on BBNX
Beta Bionics News Roundup
Here are the key news stories impacting Beta Bionics this week:
- Negative Sentiment: The securities lawsuit covers investors who purchased Beta Bionics shares between July 30, 2025, and February 24, 2026. The claims reportedly relate to alleged disclosures concerning the FDA’s concerns about the company’s iLet automated insulin-delivery system and the impact of those revelations on the stock. The allegations have not been proven. Hagens Berman securities class-action announcement
- Negative Sentiment: Additional notices cite allegations that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints. If substantiated, such claims could increase regulatory, litigation, and reputational risks for the company. SueWallSt Beta Bionics lawsuit notice
- Negative Sentiment: The high volume of investor-law-firm announcements keeps attention focused on legal exposure and prior share-price losses, weighing on investor confidence. The lead-plaintiff deadline is November 3, 2026. Kaplan Fox lead-plaintiff deadline notice
- Neutral Sentiment: Insider Mark Hopman sold 775 shares for approximately $13,446, reducing his direct ownership by 1.38%. Because the sale was small relative to his remaining 55,334 shares, it is a modest signal but may add some pressure to sentiment. SEC insider transaction filing
Insider Buying and Selling at Beta Bionics
In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the sale, the chief financial officer owned 159,378 shares of the company’s stock, valued at $3,045,713.58. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of Beta Bionics stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the transaction, the insider directly owned 87,157 shares in the company, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,472 shares of company stock worth $1,920,481 in the last ninety days. 5.30% of the stock is owned by insiders.
Institutional Investors Weigh In On Beta Bionics
Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd boosted its position in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the period. Legal & General Group Plc bought a new position in Beta Bionics during the second quarter worth $62,000. The Manufacturers Life Insurance Company bought a new position in Beta Bionics during the second quarter worth $172,000. Values First Advisors Inc. increased its position in Beta Bionics by 35.1% during the first quarter. Values First Advisors Inc. now owns 47,551 shares of the company’s stock worth $476,000 after acquiring an additional 12,360 shares during the period. Finally, Ieq Capital LLC bought a new position in Beta Bionics during the second quarter worth $229,000.
Beta Bionics Stock Down 5.5%
Shares of Beta Bionics stock opened at $16.35 on Friday. Beta Bionics has a 12-month low of $8.80 and a 12-month high of $32.71. The stock has a 50 day moving average price of $19.04 and a two-hundred day moving average price of $15.19. The stock has a market capitalization of $735.59 million, a P/E ratio of -9.91 and a beta of 3.39.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The company had revenue of $32.01 million for the quarter. Sell-side analysts anticipate that Beta Bionics will post -2.02 earnings per share for the current year.
About Beta Bionics
Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.
The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.
Read More
- Five stocks we like better than Beta Bionics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
